Antony C. Mattessich
President and CEO at Ocular Therapeutix Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Ocular Therapeutix Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Aura Biosciences Inc. June 20, 202485.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Aura Biosciences Inc. | Grant or award | +15,000 | — | — |
| Jun 17, 2025 | Aura Biosciences Inc. | Grant or award | +13,000 | — | — |
| Jun 20, 2024 | Aura Biosciences Inc. | Grant or award | +10,500 | — | — |
| Feb 5, 2024 | Ocular Therapeutix Inc. | Open-market sale | +19,642 | $4.86 | $95,460 |
| Feb 3, 2024 | Ocular Therapeutix Inc. | Grant or award | +180,400 | — | — |
| Jan 31, 2024 | Ocular Therapeutix Inc. | Open-market sale | −18,338 | $4.95 | $90,773 |
| Aug 30, 2023 | Ocular Therapeutix Inc. | Open-market purchase | +6,500 | $3.81 | $24,765 |
| Feb 6, 2023 | Ocular Therapeutix Inc. | Open-market sale | −19,669 | $4.24 | $83,397 |
| Jan 30, 2023 | Ocular Therapeutix Inc. | Grant or award | +176,300 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.